| CONFERENCE AGENDA Thursday, April 15, 1999
 |
AGENDA-AT-A-GLANCE |
7:00 a.m. - 8:00 a.m:
Registration
8:00 a.m. - 8:10 a.m.:
Welcome and Conference Objectives |
Lana R. Skirboll, Ph.D., Office of Science Policy, Office of
the Director, National Institutes of Health
Gregory J. Downing, D.O., Ph.D., Office of Science Policy, Office of the Director,
National Institutes of Health |
8:10 a.m. - 8:45 a.m.:
Plenary Session 1: Historical Perspectives
| Biomarkers as Surrogate Endpoints in Clinical
Trials for HIV/AIDS: A Model for Other Diseases? |
| Speakers: |
Donna Mildvan, M.D., Beth Israel Medical Center
Jonathan M. Kagan, Ph.D., National Institute of Allergy and Infectious Diseases |
Biomarkers as Surrogates in Clinical Research
Speaker: Scott L. Zeger, Ph.D., Johns Hopkins University School of Hygiene and Public
Health
8:45 a.m. - 9:00 a.m.:
Keynote Address: Harold Varmus, M.D., Director, National Institutes of Health
9:00 a.m. - 10:30 a.m.:
Plenary Session 2: The Need and Prospects for Biomarkers in Therapeutic Development
Moderator: John A. Oates, M.D., Vanderbilt University
Case Presentation: Contribution of Pharmacology Markers
Speaker: Paul Rolan, M.D., University of Manchester and Medeval Co., United Kingdom
| The Prospective Search for Alzheimer's Disease Biomarkers
|
| Speakers: |
B. Michael Silber, Ph.D., Pfizer, Inc.
Trey Sunderland, M.D., National Institute of Mental Health
Raj B. Parekh, M.A., D.Phil., Oxford Glycosciences |
Developing the Research Infrastructure To Evaluate Cancer Biomarkers: The Early
Detection Cancer Network
Speaker: Richard D. Klausner, M.D., Director, National Cancer Institute
10:30 a.m. - 10:45 a.m.:
BREAK
10:45 a.m. - 11:00 a.m.:
Keynote Address: Jane Henney, M.D., Commissioner, U.S. Food and Drug Administration
11:00 a.m. - 12:30 a.m.:
Plenary Session 3: Opportunities for Developing Biomarkers for CNS Disorders
Moderator: Linda S. Brady, Ph.D., National Institute of Mental Health
Biomarkers for the Experimental Therapeutics of Huntington's Disease and
Parkinson's Disease
Speaker: Ira Shoulson, M.D., University of Rochester
Imaging the Addicted Brain
Speaker: Nora D. Volkow, M.D., Brookhaven National Laboratory
Cognitive Biomarkers and the Treatment of Schizophrenia
Speaker: Barbara A. Cornblatt, Ph.D., Hillside Hospital
Genetic and Epidemiologic Basis for Developing Biomarkers of Complex Diseases.
Speaker: Kathleen R. Merikangas, Ph.D., Yale University
| Discussants: |
Stanley J. Watson, Jr., M.D., Ph.D., University of Michigan
Richard C. Mohs, Ph.D., Mount Sinai School of Medicine and Veterans Affairs Medical Center |
12:30 p.m. - 1:30 p.m.:
LUNCH
1:30 p.m. - 4:30 p.m.:
Concurrent Breakout Sessions
Click on button for detailed information on concurrent breakout sessions.
|
Biomarkers for Chronic Lung Diseases |
|
Pharmacokinetic and Pharmacodynamic Methods in
Biomarker Development and Application |
|
Neurosciences I—Neurodegenerative and
Neuropsychiatric Disorders |
|
Cardiovascular I—Acute Ischemic Coronary
Syndromes |
|
Transplantation I—Physiologic, Histologic,
and Pharmacologic Markers of Graft Function |
|
Cancer Prevention—Biomarkers and Surrogate
Endpoints in Clinical Trials |
|
Biomarkers of Joint Destruction and Repair |
|
Severe Infections and Septic Shock |
|
Neurosciences III—Biomarkers for Pain
Assessment |
4:30 p.m. - 5:30 p.m.:
Summary of Concurrent Breakout Sessions
5:30 p.m. - 7:00 p.m.:
DINNER
| 7:00 p.m. - 7:30 p.m.: |
| Keynote Address: |
John F. Niblack, Ph.D., Executive
Vice President,
Pfizer, Inc. |
7:30 p.m. - 9:30 p.m.:
Plenary Session 4: Emerging Technologies: Insight Into Novel Biomarkers
Moderator: David J. Lipman, M.D., Director, National Center for Biotechnology Information,
National Library of Medicine
From Ambiguities to Insights
Speaker: David J. Lipman, M.D.
cDNA Approaches to Analysis of Human Disease
Speaker: James H. Eberwine, Ph.D., University of Pennsylvania Medical Center
Emergent Order in Systematic Genome-Scale Observations of Variation in Gene
Expression Patterns and Its Implication for Diagnosis and Surveillance
Speaker: Patrick O. Brown, M.D., Ph.D., Howard Hughes Medical Institute and Stanford
University
SAGE and Expression Technologies—Potential Biomarker Applications
Speaker: Gregory J. Riggins, M.D., Ph.D., Duke University Medical Center
Connecting MRI Imaging Technologies With Physiology
Speaker: Robert S. Balaban, Ph.D., National Heart, Lung, and Blood Institute
Friday, April 16, 1999
7:45 a.m. - 9:30 a.m.:
Plenary Session 5: Immune and Inflammatory Markers
Moderator: Anthony S. Fauci, M.D., Director, National
Institute of Allergy and Infectious Diseases
Introduction and Overview
Speaker: Anthony S. Fauci, M.D.
Immune Memory and Protective Immunity
Speaker: Rafi Ahmed, Ph.D., Emory Vaccine Center and Emory University School of Medicine
Seeing Is Believing: Monitoring In Vivo Gene Expression by Magnetic Resonance
Imaging
Speaker: Thomas J. Meade, Ph.D., California Institute of Technology
Gene Expression in Inflammatory Disease Using Multiple DNA Array Technologies
Speaker: David H. Mack, Ph.D., Eos Biotechnology
Challenges in Discovery of Useful Biomarkers
Gordon Ringold, Ph.D., SurroMed and GlaxoWellcome
9:30 a.m. - 12:30 p.m.:
Concurrent Breakout Sessions
Click on button for detailed information on concurrent breakout sessions.
|
Biomarkers of Toxicity and Surrogate Endpoints
for Safety |
|
Osteoporosis Biomarkers and Surrogate Endpoints |
|
Biomarkers in Cancer Therapeutics |
|
Transplantation II—Immune Markers of Graft Dysfunction |
|
Immune Correlates of Protection and Recovery: Hepatitis C Virus |
|
Biomarkers in the Spectrum of Autoimmune Diseases |
|
Neurosciences II—Biomarkers for Alcohol and Drug Abuse |
|
Cardiovascular II—Stable Cardiovascular Disease |
|
Establishing the Research Infrastructure To
Develop and Classify Clinical Biomarkers |
12:30 p.m. - 1:45 p.m.:
LUNCH
1:45 p.m. - 2:45 p.m.:
Summary of Concurrent Breakout Sessions
2:45 p.m. - 3:45 p.m.:
Closing Session
Panel Discussion: Research Recommendations for Advancing the Biomarker Field
Moderator: Gregory J. Downing, D.O., Ph.D.
| Panelists: |
Robert Califf, M.D., Duke University
Steven R. Cummings, M.D., University of California, San Francisco
Donna Mildvan, M.D.
Scott L. Zeger, Ph.D. |
|
